|
|
What can we do for you?
Research:
Poll: Does shifting to commercial research give control over clinical trials?
Latest Job
Openings
|
|
Want to know about the latest research findings and hottest jobs in the Pharmaceutical and Biotechnology Industry? Then you’ve come to the right place. When you want up-to-the-minute information and job listings for Clinical Research Associates, Contract Clinical Research Associates and Clinical Trial Managers, Sterling-Hoffman Life Sciences Journal is the source to turn to.
|
|
"Research is to see what everybody else has
seen, and to think what nobody
else has thought.”
Albert
Szent-Gyorgyi, (Biochemist, 1937 Nobel Prize
for Medicine,1893-1986)
|
By Rishab K. Gupta, Ph. D., Professor Emeritus, Division of Oncology, Department of Surgery, and David Geffen School of Medicine at UCLA and Past Director of Research Core Services, and Immunodiagnosis & Protein Biochemistry, John Wayne Cancer Institute
 The
main goal in any medical investigation is to
discover effective therapeutic agents and
validate their effectiveness through
clinical trials. These trials involve a large
number of subjects in all arms of the trial to
assess statistical significance of clinical
outcome in response to the therapeutic agent. To
achieve the clinical outcome as an endpoint, the
trials are lengthy and expensive. It is highly
appropriate to take advantage of these trials to
incorporate possible surrogate biomarkers to
identify which markers are reliable for early
detection of disease.
Read full article
|
|
|
By Akulapalli Sudhakar, M. Sc., M. Phill., Ph. D, Assistant Professor and Staff Scientist II Director and Coordinator, Cell Signaling and Tumor Angiogenesis Laboratory, Boys Town National Research Hospital
 Angiogenesis,
the formation of new blood vessels, is likely to
be regulated by a balance between endogenous proangiogenic and antiangiogenic factors. In the
normal physiological human body, equilibrium is
maintained between the proangiogenic and
antiangiogenic factors. The antiangiogenic
factors (molecules), generated by the proteolytic cleavage of the extracellular
matrix, include,
α1 chain non-collagenous (NC1)
domain of type XVIII collagen (endostatin) and
some of the type IV collagen NC1 domains
considered as endogenous angiogenesis
inhibitors.
Read full article
|
|
Hot
Job Openings
Looking to change jobs?
Find that perfect career fit with one of the hot
job openings below.
View more
jobs
|
Quality Engineer
Toronto, ON |
Apply Now |
Senior Project Manager
New York |
Apply Now |
Clinical Research Associate
Pennsylvania |
Apply Now |
Clinical Data Specialist
North Carolina |
Apply Now |
Associate Director of Quality Assurance
Silicon Valley, Northern California |
Apply
Now |
Senior Clinical Research Associate
New Jersey |
Apply
Now |
Manager, Regulatory Affairs and Compliance
Virginia |
Apply
Now |
Clinical Service Manager
Northern California |
Apply
Now |
Senior Regulatory Affairs Manager
Texas |
Apply
Now |
Clinical Project Manager
East Coast, USA |
Apply
Now |
Senior Clinical Research Associate
New Jersey |
Apply
Now |
Director of Clinical Development
Elizabeth, NJ |
Apply
Now |
Clinical Operations Manager
New Jersey |
Apply
Now |
Regulatory Affairs Manager
Dallas, TX |
Apply
Now |
Clinical Project Manager
Columbia, MD |
Apply
Now |
Contract Clinical Research Associate
Toronto, ON |
Apply
Now |
Project Manager
New Jersey |
Apply
Now |
Clinical Project Manager
Texas |
Apply
Now |
Regulatory Affairs Manager
San Diego, CA |
Apply
Now |
Senior Clinical Research Associate
New Jersey |
Apply
Now |
Clinical Project Manager
Toronto, ON |
Apply
Now |
Senior Clinical Research Associate
Texas |
Apply
Now |
Clinical Study Manager
New Jersey |
Apply Now |
Director of Clinical Trials
Maryland |
Apply Now |
Senior Clinical Research Associate
New Jersey |
Apply
Now |
Clinical Project Manager
Midwest, USA |
Apply
Now |
View more jobs
|
Send us your
resume | |
 |
|
| |
|
